{"id":1618,"date":"2023-01-09T08:00:00","date_gmt":"2023-01-09T07:00:00","guid":{"rendered":"https:\/\/d3glparxwv1yl3.cloudfront.net\/annualreport\/press-releases\/ipsen-to-acquire-albireo-accelerating-growth-in-rare-disease-with-treatments-for-several-pediatric-liver-diseases\/"},"modified":"2023-05-23T14:11:18","modified_gmt":"2023-05-23T14:11:18","slug":"ipsen-to-acquire-albireo-accelerating-growth-in-rare-disease-with-treatments-for-several-pediatric-liver-diseases","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/annualreport\/press-releases\/ipsen-to-acquire-albireo-accelerating-growth-in-rare-disease-with-treatments-for-several-pediatric-liver-diseases\/","title":{"rendered":"Ipsen to acquire Albireo accelerating growth in rare disease with treatments for several pediatric liver diseases"},"content":{"rendered":"
PARIS, FRANCE & BOSTON, U.S.,<\/strong>\u00a009 January 2023 \u2013 Ipsen (Euronext: IPN: ADR: IPSEY) and Albireo (Nasdaq: ALBO) today announced that they have entered into a definitive merger agreement under which Ipsen will acquire Albireo, a leading innovator in bile-acid modulators to treat pediatric and adult cholestatic liver diseases. The anticipated acquisition will enrich Ipsen\u2019s Rare Disease portfolio and pipeline.<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"template":"","categories":[],"tags":[],"class_list":["post-1618","press_release","type-press_release","status-publish","hentry","entry"],"acf":[],"yoast_head":"\n